Public Citizen Testimony on Cryptocurrency Mining in Texas

Testimony on Cryptocurrency Mining in Texas

Testimony Public Citizen Texas Director Adrian Shelley on cryptocurrency mining in Texas, delivered before the Texas Senate Business and Commerce Committee

Webinar: Stopping Trade Attacks on Climate Policies

Learn how trade rules are impending climate action and what we can do about it.

Testimony on Cryptocurrency Mining in Texas

Letter to Congress on World Diabetes Day: Expand Access to Insulin and Lower Prices

Testimony on Cryptocurrency Mining in Texas

Public Citizen, T1International and more than 50 organizations wrote to Congress on World Diabetes Day, November 14, 2022, urging congressional leaders to pass insulin legislation. Signatories to the letter outlined that legislation should both 1) ensure people without insurance and with private insurance, who are most vulnerable to rationing, have access to the insulin they need and 2) stop corporations that manufacture insulin from charging excessive prices.


November 14, 2022

Dear Majority Leader Schumer, Speaker Pelosi, Minority Leader McConnell, and Minority Leader McCarthy,

Today on World Diabetes Day, our organizations call on Congress to urgently pass legislation to ensure that people in the United States have affordable access to the insulin that they need to live. World Diabetes Day marks the birthday of Frederick Banting, who discovered insulin and famously sold its patent for $1 and stated, “Insulin does not belong to me, it belongs to the world.”[1] Despite its discovery more than 100 years ago and the generosity of Banting and the co-inventors, many people living in the United States still struggle to afford access to the insulin they need.

We are grateful for the progress made recently through the passage of the Inflation Reduction Act that will limit Medicare Part D beneficiaries’ monthly out-of-pocket costs for each insulin prescription to $35. And, this reform barely scratches the surface of what is needed to truly expand insulin access and likely does nothing to lower the excessive prices charged by insulin manufacturers.[2]

A recent study published in the Annals of Internal Medicines found that 1.3 million people in the United States ration insulin.[3] Another recent survey showed as many as 1 in 4 people with type 1 diabetes ration insulin.[4] People without insurance were most likely to ration insulin (29.2% ration insulin), followed by those with private insurance (18.8%).[5] Rationing is disproportionately high for Black Americans, of whom 23.2% ration insulin, compared with 16% of Hispanic and White Americans.[6]

As people in the United States struggle to access affordable insulin, the big three drug corporations that manufacture insulin have repeatedly and sharply raised prices and aggressively sought to extend lucrative product monopolies, resulting in many billions of dollars in excessive spending.[7]

Any insulin reform legislation advanced by legislators must achieve two essential goals:

  • Ensure people without insurance and people with private insurance, who are most vulnerable to rationing, have access to the insulin they need.

Alec Smith was 26 years old when he aged out of his parents’ health insurance. [8] He made just enough not to qualify for insurance subsidy or patient assistance programs, meaning, like many people without insurance, he was forced to face the full price for his insulin out of pocket. As a result, Alec rationed his insulin supply to wait to afford more, but within days, he died of ketoacidosis.

Any insulin legislation that would not have prevented this tragedy fails the Alec Smith test. It is vital that affordable insulin access is provided to everyone who does not have insurance, in addition to those who are privately insured.

  • Stop insulin manufacturers from charging excessive prices.

Since the 1990’s, insulin manufacturers have raised prices many times over for U.S. patients, as much as 1100%, despite their products remaining largely unchanged, and low production costs.[9]

Abusive pricing of insulin, which the very same corporations who sell insulin here sell for a fraction of the price in other wealthy countries, [10] has led to immense profits for these corporations at the cost of preventable suffering and death of people who need insulin, in addition to billions of dollars drained from government coffers and consumers’ bank accounts.

Any insulin legislation that fails to lower the prices charged by insulin manufacturers would fail to hold these corporations accountable, in effect rewarding them for decades of price gouging. Legislation reining in insulin prices should not take a carrot-only approach or rely on voluntary concessions from insulin manufacturers to do so.

Thank you again for your time and attention. We look forward to working with you to deliver meaningful reform that will ensure everyone, including people without insurance, have access to insulin and to lower unfair and excessive prices.

Sincerely,

ACA Consumer Advocacy
American Academy of Family Physicians
American-Arab Anti-Discrimination Committee (ADC)
Beta Cell Foundation
Colorado Consumer Health Initiative (CCHI)
Community Catalyst
Congregation of Our Lady of Charity of the Good Shepherd, U.S. Provinces
Connecticut #insulin4all Chapter
Covid-19 Longhauler Advocacy Project
Dana Investment Advisors
Doctors for America
Domini Impact Investments LLC
Dominican Sisters ~ Grand Rapids (MI)
Families United For Affordable Insulin
Families USA
Family Voices
Fayetteville Police Accountability Community Taskforce
Florida #insulin4all Chapter
Generation Patient
Health Access California
Health Care Voices
Idaho #insulin4all Chapter
Indivisible
Interfaith Center on Corporate Responsibility
Just Care USA
Maryland Health Care for All! Coalition
Medicare Rights Center
Michigan #insulin4all Chapter
Minnesota #insulin4all Chapter
Mutual Aid Diabetes
National Advocacy Center of the Sisters of the Good Shepherd
National Association of Councils on Developmental Disabilities
National Council of Jewish Women
National Health Law Program
NC Justice Center
National Domestic Workers Alliance (NDWA)
Network Lobby for Catholic Social Justice
New York #insulin4all Chapter
North Carolina Medicare For All Coalition
Northwest Coalition for Responsible Investment
Ohio #insulin4all Chapter
Oregonizers
People’s Action
Physicians for a National Health Program
Public Citizen
Right to Health Action
Seventh Generation Interfaith Coalition for Responsible Investment
Sisters of Charity of Saint Elizabeth
Sisters of St. Francis Dubuque
Social Security Works
T1International
The Diabetes Link @ Yale
The Insulin Initiative
United Church of Christ Justice and Local Church Ministries
Utah #insulin4all Chapter

[1] https://www.t1international.com/100years/

[2] https://www.citizen.org/article/prices-for-leading-insulins-will-likely-not-be-negotiated-under-new-drug-pricing-package/

[3] https://www.acpjournals.org/doi/full/10.7326/M22-2477

[4] https://www.sciencedirect.com/science/article/pii/S0168822721003557

[5] https://www.acpjournals.org/doi/full/10.7326/M22-2477

[6] https://www.acpjournals.org/doi/full/10.7326/M22-2477

[7] https://oversight.house.gov/sites/democrats.oversight.house.gov/files/DRUG%20PRICING%20REPORT%20WITH%20APPENDIX%20v3.pdf

[8] https://www.pbs.org/wgbh/blood-sugar-rising/home/portraits/the-smithholt-family/

[9] https://www.nbcnews.com/business/consumer/desperate-families-driven-black-market-insulin-n730026

[10] https://www.rand.org/pubs/research_reports/RRA788-1.html

Public Citizen Town Hall

Public Citizen's top directors answered questions from our members on today's issues.

Testimony on Cryptocurrency Mining in Texas

Public Citizen President, Robert Weissman and Executive Vice President, Lisa Gilbert talked to members about the 2022 Midterms.

Impact Natural Gas Exports Have on Destabilizing the New England Energy Market

By Tyson Slocum

Testimony on Cryptocurrency Mining in Texas

Today in Federal Energy Regulatory Commission Docket AD22-9, we ask ISO-NE and other stakeholders to ask the U.S. Department of Energy to declare that exports of natural gas are inconsistent with the public interest, and ensure that New England’s needs are prioritized over exports; and request Commission action under 15 USC § 717t–2(a)(4) to establish an RTO for spot natural gas trading in New England in order to improve market transparency. Read the filing here: ISONEgas

Letter to Dept of Energy To Protect Consumers From LNG Exports

By Tyson Slocum

Testimony on Cryptocurrency Mining in Texas

On October 27, 2022, Public Citizen joined with national and regional consumer groups to ask to the Department of Energy to initiate a rulemaking to take into account the impact record LNG exports are having on exacerbating energy poverty and income inequality in the United States. Read the petition here ConsumerPetitionLNGexports

Toyota Zero Emission Vehicle Coalition Letter

Testimony on Cryptocurrency Mining in Texas

Read the PDF here. 

CEO Akio Toyoda
1 Toyota-Cho, Toyota City
Aichi 471-8571
Japan

November 4, 2022

Dear CEO Akio Toyoda,

As consumer and environmental groups representing millions of members and supporters, we write to express deep concern and disappointment over your recent comments on electric vehicles (EVs) in Las Vegas, Nevada. You stated that it will be “difficult” to comply with rules phasing out the sale of internal combustion engines by 2035, said that Toyota will not change its strategy on EVs, and claimed to be following consumer demand. These remarks are divorced from reality and are unacceptable. They also follow a disturbing pattern of conduct. Your company has been exceedingly slow to produce EVs and has lobbied to delay their adoption so rigorously that you have been ranked the third most obstructive organization in the world on climate policy, behind only the notorious climate-denying oil giants Chevron and ExxonMobil. 

One recent media report suggests that your company may be changing its EV strategy. If true, this is a welcome and necessary development. However, given that this contradicts statements you made in your capacity as the CEO of Toyota just weeks earlier, we will assume that Toyota’s strategy remains unchanged until you make an official announcement to the contrary.

No automaker has been able to keep up with the surging consumer demand for battery electric vehicles, but Toyota has not even attempted to meet it. Over one third of Americans already plan to buy or lease an EV or are seriously considering doing so, and polls show that fifty-five percent of U.S. voters support requiring manufacturers to sell only electric vehicles by 2030. You have only offered one EV model for sale, beginning in 2022, a full decade after Tesla demonstrated that there is a strong market for electric vehicles. 

Your competitors  have made much more progress and plan to go fully electric at a much quicker pace: General Motors, Volvo, Mercedes-Benz, and Ford have committed to work towards 100% zero-emission new car and van sales in leading markets by 2035. New Audi models will all be fully electric starting in 2026 and it will end internal combustion engine vehicle sales in 2035. Even your subsidiary Lexus has said it will produce only battery electric vehicles by 2035.

Your refusal to lead a rapid transition to electric vehicles and your advocacy against ZEV policies not only contradicts what consumers want, but also harms them. In addition to causing climate change, air pollution from burning fossil fuels is responsible for one in five deaths globally. The positive impact from Toyota producing hybrids, including plug-in hybrid electric vehicles (PHEVs), does not outweigh the harm from your opposition to EVs, your decade of cheating on emissions testing, or the poor fuel efficiency of your fleet overall. Additionally, your executives have overstated the benefits of PHEVs: recent research shows that their real-world fuel consumption and carbon emissions are on average three to five times higher than expected.

EVs are the future: with no tailpipe emissions, they’re better for our health and essential to keeping our planet livable. Increasingly, zero-emission vehicles are also required by law. Toyota can and must shift swiftly to EVs or risk obsolescence. Toyota Motor Corporation must:

  1. phase out internal combustion engine vehicles (including hybrids and plug-in hybrids) in the U.S. and Europe by 2030 and globally by 2035;
  2. align advocacy and lobbying with the goal of phasing out internal combustion engines, and be a voice for 100% renewable energy economy-wide;
  3. require 100% renewable energy use throughout your supply chains globally by 2035;
  4. align with SteelZero Commitment to source 100% net zero steel by 2050, with an interim commitment of using 50% responsibly produced steel by 2030, without relying on carbon offsets; and
  5. require that the minerals in your electric vehicle batteries are sourced responsibly, and develop battery design that allows for easy reuse and recycling of minerals.

These measures will do more than just meet your ethical responsibilities. They will position Toyota as an industry leader for decades to come.

We request a meeting to discuss these issues and look forward to your response by November 30, 2022. 

Sincerely,

 

Public Citizen

350 Sacramento

Austrian Sustainable Mobility  

Better New Zealand Trust

Center for Community Action and Environmental Justice

Coltura

Elders Climate Action

Environmental Working Group

EVDrivers, A.C.

Interfaith Power and Light

Let’s Green CA!

Mighty Earth

Project Green Home

SanDiego350

Stand.earth

SumOfUs

The Sunrise Project

Read the PDF here.

Public Citizen Sends Letter to Indian Ambassador on Concerns About Proposed Trade Deal

Provisions Would Limit Access to Medicines

Testimony on Cryptocurrency Mining in Texas

The Honorable Taranjit Singh Sandhu
Ambassador, Republic of India
2107 Massachusetts Avenue, NW
Washington, DC 20008

Dear Ambassador Sandhu,

Public Citizen is a consumer advocacy group based in Washington, DC with 500,000 members and supporters and a fifty-year history advocating for public interests before Congress, the executive branch agencies and the courts. Long have we supported India’s critical role as pharmacy to the developing world. Frequently Public Citizen has emphasized to the U.S. government and international organizations the importance of India’s policies exercising and preserving flexibilities in international law to protect global access to medicines.

We write to you today with grave concern about the impact of a proposed United Kingdom-India Free Trade Agreement. In our work with partners around the world, we have seen first-hand the transformative impact of Indian generics on public health. Indeed, the Indian pharmaceutical industry is widely lauded by the global community for its vital role as a supplier of affordable lifesaving medicines. The draft UK-India Free Trade Agreement threatens this achievement.

The leaked chapter on intellectual property places obligations that go well-beyond what is required by the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights and would undermine public health safeguards enshrined in Indian law.

Principle among these is Section 3(d) of the Patents Act, which establishes a robust standard of what is considered patentable. If adopted, the FTA would effectively gut Section 3(d) and make it easier for pharmaceutical corporations to establish thickets of patents around lifesaving medicines. As governments around the world, including the U.S., consider how to rein in out-of-control patenting, the FTA would require India to do just the opposite by making it easier for corporations to obtain monopolies. In addition, the FTA would also prohibit pre-grant patent oppositions and introduce additional monopoly protection in the form of patent term extensions and data exclusivity, among other harmful provisions.

Each of these measures alone could damage medicine access. Together, their impact would be deeply harmful. The provisions would throttle generic competition, entrench the dominance of large pharmaceutical corporations, and result in increased medicine prices, hurting patients. The ripple effects of adopting this lopsided deal would be felt around the world.

In our work in Latin America and in Africa, we have often pointed to the Indian patent law for its rigorous, balanced approach to public health. The UK-India FTA imperils this balance. We urge India to stand firm and reject these provisions, and to refuse to trade away health. High-income countries, like the United Kingdom, should seek to emulate Indian patent law, not the other way around.

Sincerely,

Peter Maybarduk
Director, Access to Medicines Program
Public Citizen

Protecting the Profiteer

Testimony on Cryptocurrency Mining in Texas

Key Findings

The Groundwork Collaborative and Public Citizen analyzed the lobbying around 27 anti-price gouging and profiteering bills introduced since early 2021. Our analysis revealed that while many households struggled to make ends meet, due in large part to rising prices, companies reaping historic profits deployed their lobbying power to Capitol Hill to fight attempts to crack down on price gouging and profiteering, overwhelming the bill supporters by enormous margins. In other words, corporate America – and its aligned trade groups – used their lobbying power to thwart almost all attempts by Congress to curb price gouging and profiteering.

This analysis focuses on lobbyist engagements, which are instances in which a company, trade group, or non-profit, hires a lobbyist to lobby for or against a bill. Our key findings include:

  • Those opposing anti-price gouging and profiteering bills were responsible for more than 2,600 lobbyist engagements on Capitol Hill. Supporters were responsible for fewer than 300, giving those opposed to anti-price gouging legislation a 9-to-1 advantage.
  • Two of the country’s largest corporate trade associations opposed to the anti-price gouging bills in this analysis, PhRMA and the Chamber of Commerce, blanketed Capitol Hill with more or almost as many lobbyist engagements as the supporters of all of the bills combined. PhRMA was responsible for 436 engagements, 1.5 times more than all the bill supporters combined (286). The Chamber was responsible for 274, nearly as many as the bill supporters.
  • H.R.3, the Elijah E. Cummings’ Lower Drug Costs Now Act (the signature drug pricing reform bill of the Democrats in the House) resulted in 1,157 lobbyist engagements, the most of any bill in this analysis. 96% of the engagements (1,110) came from corporations, trade groups, and non-profits opposed to the bill, giving the opposition a 24-to-1 advantage.

Corporations Have Taken Advantage of Rising Prices, Supply Chain Disruptions, and the War in Ukraine to Boost Prices and Pad Their Bottom Lines

Since September of 2021, prices for everything from essential household items, to food, to cars and gas have been on the rise. Overall inflation – as measured by the Consumer Price Index (CPI) – has risen 8.2% and in key areas rising prices have squeezed household budgets and driven hardship for low and moderate-income families. Prices for food, housing, and energy, have shot up 11.2%, 6.6%, and 19.8%, respectively, over the same time period.[1]

These price increases have been driven by a host of factors. Many have noted that supply chain disruptions have made it increasingly difficult for companies to quickly move products to meet consumer demand. And the war in Ukraine has similarly exerted an upward force on food and energy prices as crucial supplies of wheat and oil have been constrained, leading to supply and demand imbalances on global markets. But what has garnered less attention is the role of corporate profiteering in further exacerbating inflation – that is, the explicit choice of corporations to take advantage of the pandemic and the uncertainty generated by the war in Ukraine to raise prices well above what increased input costs would require in order to boost profits and enrich their shareholders.

On earnings calls, a quarterly or annual conference call between the management of a public company, shareholders, and the media to discuss the company’s financials – CEOs and other high-ranking executives across multiple sectors and industries have made it repeatedly clear to shareholders that they are aggressively increasing prices to boost profits, simply because they can.[2]

Recent research has drawn clear lines between outsized corporate profits – and, more importantly, profit margins – and the inflation that people are experiencing. An analysis from the Roosevelt Institute found that firms with high levels of market concentration prior to 2020 were able take advantage of the pandemic to significantly increase their profit margins and drive up prices.[3] Research conducted by the Economic Policy Institute went further and found that rising corporate profit margins accounted for roughly 40% of the rise in prices since the pandemic.[4]

Corporations have been able to pass along higher prices relative to past recessions for three major reasons:

  • First, decades of government deregulation and market consolidation have given large corporations in specific sectors – for example, meatpacking, shipping, and household essentials – such high levels of market control that consumers, or other businesses dependent on their services, have no choice but to accept higher prices. And such high levels of corporate concentration have not only worked to raise prices directly for consumers, but have also undermined our supply chains. Monopoly power has hollowed out and nearly eliminated supply chain redundancies, leaving the private sector without enough geographic diversification or productive capacity to withstand significant shifts in demand or COVID-induced closures without supply shortages – leading to further price increases.
  • Second, many items where prices have gone up significantly are essential items. Medicines and life-saving drugs, for example, are what economists call “price inelastic,” which means that raising the price of the good does not drastically lower demand. That means that companies can raise prices to fatten their profit margins and reward their shareholders without losing consumers. Corporations have, in their own words, corroborated this, noting that despite price increases, demand remains strong.[5] In a recent earnings call, Johnson & Johnson told analysts that their sales increases “were primarily driven by strategic price increases” and declared “our strategy is working” as their own supply chain issues ease and their price hikes take full effect. Rather than easing prices for consumers, they’re using excess profits for $13 billion worth of stock buybacks and dividends.[6] In the pharmaceutical space, one 2021 analysis found that over 830 drugs increased in price, on average, by 4.6% from the year prior. By comparison, from 2017 through 2020, on average, only 705 drugs saw price increases in a given year.[7]
  • Third, the pandemic has provided companies with “cover” as supply chain disruptions, inflation spurred on by the post-pandemic recovery, and cost increases associated with the war in Ukraine, make it harder for consumers to discern what are legitimate price increases and what constitutes corporate profiteering. This lack of clarity reduces the risk that price increases will lead to backlash from consumers. Again, corporations have acknowledged this and are taking advantage. For example, on an earnings call in late 2021 ConocoPhillips’s CEO said the company was no longer hedging for lower prices: “we expect to fully capture the upside of the current price environment.”[8]

These aggressive price hikes have gone well beyond necessary to cover additional input costs and as there are indications that production costs are falling. Global supply chain pressures, for example, decreased in September – falling nearly 30% month over month – and corporations have signaled that they intend to keep prices high.[9] A CEO of one Fortune 500 company said they had increased pricing due to inflation and “that following periods of higher inflation, our industry has historically not reduced pricing to reflect lower ultimate cost.”[10]

Unsurprisingly, squeezing consumers in times of crisis and boosting prices well above necessary has been very lucrative. Despite slowing economic growth, as of June 2022, nonfinancial corporate profits totaled over $2 trillion, the highest amount ever recorded – growing by more than 11% from the same point in 2021, which itself had been a record-breaking year.[11] Corporations are also seeing record-breaking profit margins – the difference between sales revenue and costs. Last year, margins reached over 16%, the highest on record since 1950. And the most recent quarter’s corporate profit margins of 15.8% are still well above historical averages.[12]

Companies across industries have enjoyed lavish profits. The three biggest U.S. oil companies – ExxonMobil, Chevron, and Marathon Petroleum – saw profits increase by almost $90 billion in FY 2021.[13] The biggest pharmaceutical companies – Johnson & Johnson, Pfizer, and AbbVie – saw profits rise by over 90% to $54 billion.[14]

Booming corporate profits and fatter profit margins have not gone unnoticed. Consumers and policymakers alike have become increasingly aware that corporations are taking advantage of the moment and, in response, lawmakers have proposed various bills designed to hold corporations accountable and address rampant price gouging. This report demonstrates that many of the same companies enjoying record profits – including household names such as Chevron, Johnson and Johnson, and Pfizer – are also deploying lobbyists to block these very proposals.

The Groundwork Collaborative and Public Citizen analyzed 27 different bills aimed at addressing price gouging and profiteering. As of the time of this writing, none of the bills have become law (a full list of bills can be found in the Appendix).

These bills vary in subject matter from cracking down on price gouging on drug prices and items crucial during a pandemic, to taxing windfall profits and curbing predatory overdraft fees. But the common thread through all these bills is that they are all focused on holding corporations accountable and providing relief to Americans who are struggling in the midst of a pandemic and record inflation.

9-to-1: Those Opposing Anti-Price Gouging and Profiteering Bills Blanketed Capitol Hill With More Than 2,600 Lobbyist Engagements, Bill Supporters Accounted for Fewer Than 300

Public Citizen and the Groundwork Collaborative analyzed all federal lobbying disclosures submitted from the first quarter of 2020 through the third quarter of 2022. We searched the filings for instances in which a corporation, trade group or non-profit deployed a lobbyist to lobby on one or more of the 27 bills to address price gouging or profiteering.

Doing so revealed more than 3,400 instances in which a lobbyist was hired to lobby on one of the bills (hereinafter, “lobbyists engagements”). Through a detailed process of using public statements, coalition affiliations and reaching out to the lobbying entity, we were able to determine positions of likely or firm support or opposition to one or more of the 27 bills for 2,928 lobbying engagements, 86% of the total engagements. The remaining lobbying entities either had a neutral position or we were unable to obtain any position. A detailed methodology can be found in the Appendix.

Of the engagements for which we were able to obtain a position, 90% came from entities opposing the bills proposing to prohibit or crack down on price gouging and profiteering. Those opposing the bills accounted for 2,642 lobbyist engagements while those supporting the bills accounted for just 286.

To put it another way, forces opposed to the bills were responsible for more than nine times as many lobbyist engagements as those supportive of the bills. [Figure 1]

Bills aimed at combating price gouging and profiteering related to drug prices accounted for 80% of all the lobbyist engagements. And 93% of these drug price bill engagements came from those opposing the bills. [Table 1]

The bill that produced the most lobbyist engagements by far was H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act. H.R.3 is House Democrats’ signature drug pricing reform bill. An earlier version of the bill passed the House at the end of 2019. 96% of the lobbyist engagements related to H.R.3 were in opposition. [Table 2]

PhRMA and The Chamber of Commerce Produced More or Almost as Many Lobbyist Engagements as The Entities in Support of All the Bills, Combined

The Pharmaceutical Research and Manufacturers of America (PhRMA), the main pharmaceutical industry trade group that is opposed to all the drug pricing bills in this analysis, blanketed Capitol Hill with 436 lobbyist engagements. The total amounts to 1.5 times more lobbyist engagements than all the combined engagements produced by bill supporters (286).

The Chamber of Commerce, the nation’s largest business lobby opposed to all the bills, was responsible for the second most lobbyist engagements, 274, nearly equal to the bill supporters’ total.

The Biotechnology Innovation Organization, the biotechnology trade association, ranked third, with 217 lobbyist engagements opposed to the bills. GSK (GlaxoSmithKline) and Genentech, two pharmaceutical companies, rounded out the top five with 113 and 73 lobbyist engagements in opposition, respectively. None of the top 10 entities responsible for the most lobbyist engagements were supportive of the anti-price gouging and profiteering bills. [Table 3]

There is no organization in the country that has more influence over drug price policy than PhRMA.

For example, almost all entities in the top 10 in terms of lobbyist engagements have a connection to PhRMA, either through membership or money. The six drug companies in the top 10 are all PhRMA members.[15] The Biotechnology Innovation Organization, the group with the third most lobbyist engagements, received a donation of nearly $1.1 million from PhRMA in 2019.[16]

PhRMA has in the past donated money to the Chamber of Commerce,[17] the dark money group responsible for the second most lobbyist engagements in this analysis. “Dark money group” is a term used to describe non-profits that raise and spend money to influence elections and public policy but do not disclose their donors. While dark money groups make up a small number of the nearly 200 entities lobbying on the bills in this analysis, they have an outsize influence in public policy. The Chamber of Commerce is arguably the most powerful dark money group in the country.

In total, 16 entities lobbying against the anti-price gouging and profiteering bills in this analysis donated more than $12 million combined to the Chamber in the past, according to an analysis by Issue One published in early 2018.[18] The Chamber, along with its' 16 donors, were responsible for a combined total of more than 1,300 lobbyist engagements. The total amounts to 49% of all the lobbyist engagements in opposition to the bills covered in this analysis. Thus, almost half of the opposition came from a single dark money group and corporations and special interests that have donated to the dark money group in the past. And this is very likely a conservative estimate. We only know about these Chamber donors because the donors themselves disclosed the contributions.

While our analysis focuses on entities that lobbied on the anti-price gouging and profiteering legislation, other dark money groups that did not lobby were involved in efforts to oppose bills by running ad campaigns against the bills. (Ad campaigns and other “grass-roots” lobbying efforts are not reported under the Lobbying Disclosure Act as “lobbying activities.”) And these efforts were in part funded by groups that did lobby.

For example, two weeks after Rep. Frank Pallone (D-NJ) introduced H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act in April 2021, the dark money group the American Action Network (AAN)[19] purchased a $4 million ad buy to try and kill the bill, calling it a “socialist drug takeover plan.”[20]

AAN does not disclose its donors. But because PhRMA discloses its donations, we know it gave AAN $4.5 million in 2019.[12] This was after PhRMA gave AAN $2.5 million in 2018[22] and $1.5 million in 2017.[23]

Entities Opposed to the Bills Have Spent $820 Million on Political Activity During the 2022 Cycle Thus Far, Six Times More Than Supporters

Sending lobbyists to Capitol Hill is just one of the tools corporations and trade groups use to oppose bills that restrict or end their ability to profiteer or price gouge.

According to data from OpenSecrets.org, during the 2022 election cycle thus far, those opposed to anti-price gouging and profiteering legislation have spent more than six times – $820 million vs. $129 million – as much as the bill supporters on disclosed political activity, which consists of lobbying expenditures and money spent to influence elections.

Nearly 90% of this money was spent on lobbying. The money spent on lobbying by these entities includes lobbying done on all issues and all bills, not just the bills covered in our analysis. [Figure 2]

As is the case with total lobbyist engagements, PhRMA and the Chamber of Commerce – two groups vehemently opposed to any anti-price gouging or profiteering bill – lead the pack on political spending. The Chamber of Commerce has spent the most during the 2022 cycle thus far, almost $130 million, while PhRMA has spent $53 million, the second most.

When it comes to conventional electioneering spending (e.g., contributions to candidates, PACs, party committees or other outside groups), those opposed to the bills have outspent bill supporters by $20 million during the 2022 cycle thus far – $68 million to $48 million.

Conclusion

Failing to address inflation and its underlying drivers will mean more hardship for everyday people while powerful corporations and their shareholders continue to reap the rewards. Tackling the drivers of high prices – the pandemic, supply chain disruptions and the war in Ukraine – is important, and policymakers have already made some positive strides toward addressing these very issues.

In August of this year, Congress passed the Inflation Reduction Act.[24] The drug pricing provisions included in the bill will help combat some drug price gouging. The bill empowers Medicare to negotiate drug prices on a limited number of older drugs, with the first set of negotiated prices available to patients beginning in 2026.

The bill also requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation and it caps the cost of a monthly supply of insulin at $35 for Medicare patients. It redesigns the Medicare Part D benefit to provide more incentive for Part D plans to obtain lower prices and cover lower-cost medicines, and puts in place a $2,000 annual out-of-pocket cap for all beneficiaries.

While the Inflation Reduction Act is a big step in the right direction and a major blow to the pharmaceutical industry, it has its limits and more can be done. Beyond pharmaceuticals, lawmakers must understand how outsized corporate power has allowed large corporations across many sectors to take advantage of consumers in this moment and act accordingly. Tackling pandemic profiteering and building a healthy, resilient economy requires checking the outsized power that megacorporations hold over our economy. Congress must do its part to address corporate concentration and rein in the unchecked power that these megacorporations exert on prices and our democracy.

Congress should ensure rigorous competition in key product markets at critical nodes along the supply chain by curtailing mergers that further concentrate industries or by breaking up monopolies. The passage of the Ocean Shipping Reform Act, for example, is an encouraging development that will help to re-regulate the large ocean shipping monopolies that are stoking inflation and gumming up critical points in our supply chain.

Lawmakers must strengthen antitrust laws already on the books and continue to urge the FTC to use their existing authority to crack down on extractive and exploitative business practices, including price gouging, as well as further empower regulators at both the state and federal level to identify price gouging and protect consumers. This should include a federal price gouging statute to curtail exploitative pricing during emergencies and targeted price controls where appropriate.

Policymakers should also consider enacting an excess profits tax to reduce the incentive for companies to engage in profiteering behavior as any outsized profits that accrue over a certain threshold are taxed away and diverted to public coffers. Such an approach is not new – as recently as the 1980s, the US had in place a windfall profits tax on oil companies.[25]

Furthermore, spending activity to influence legislation should not be so difficult to uncover. The Lobbying Disclosure Act (LDA) should capture campaign ads and other grass-roots activities that call upon the public to contact government officials to influence legislation as reportable lobbying activities. The DISCLOSE Act – legislation that would require non-profits to disclose their sources of funds used for political purposes and bring an end to dark money – should become the law of the land. President Biden should also exercise executive authority to issue the proposed executive order requiring government contractors to disclose their political spending.

To accomplish this, elected officials must push back against the lobbying onslaught by corporations very much invested in maintaining the status quo.

References

[1] Analysis of Bureau of Labor Statistics Data, Groundwork Collaborative, https://bit.ly/3U4Mg6p.

[2] Groundwork Collaborative staff have listened in on hundreds of earnings calls, where, by law, companies must tell the truth about their company finances and corporate pricing strategies. For a full collection of relevant quotes from publicly traded companies visit www.endcorporateprofiteering.org. See also, Lindsay Owens, I Listened In on Big Business. It’s Profiting From Inflation, and You’re Paying for It. The New York Times (May 5, 2022), https://nyti.ms/3DiSvgf.

[3] Mike Konczal and Niko Lusiani, Prices, Profits, and Power: An Analysis of 2021 Firm-Level Markups, Roosevelt Institute (June 21, 2022), https://bit.ly/3sGlQfW.

[4] Josh Bivens, Inflation, minimum wages, and profits, Protecting low-wage workers from inflation means raising the minimum wage, Economic Policy Institute (Sept. 22, 2022), https://bit.ly/3U3Ur35.

[5] Kimberly-Clark Corporation (KMB) CEO Mike Hsu on Q4 2021 Results – Earnings Call Transcript, Seeking Alpha (Jan. 6, 2022), https://bit.ly/3TODkCH.

[6] Johnson & Johnson (JNJ) Q3 2022 Earnings Call Transcript, Motley Fool (Oct. 18, 2022), https://bit.ly/3FmzL29.

[7] Tori Marsh, 800+ Drugs Became More Expensive This January — The Largest Number of Increases in Years, GoodRX Health (Feb. 2, 2021), https://bit.ly/3FzNgeK.

[8] ConocoPhillips (COP) Q4 2021 Earnings Call Transcript, The Motley Fool (Feb. 3, 2022), https://bit.ly/3zpmzpk.

[9] Groundwork Collaborative analysis, Global Supply Chain Pressure Index (GSCPI), Federal Reserve Bank of New York (Estimates for Sept. 2022), https://nyfed.org/3U3whWk and Research, End Corporate Profiteering, Groundwork Collaborative, https://endcorporateprofiteering.org/.

[10] Autozone, Inc. (AZO) Q3 2022 Earnings Call Transcript, AlphaStreet, (May 25, 2022), https://bit.ly/3NfX4fQ.

[11] Groundwork Collaborative analysis, National Income and Product Accounts Table 1.14., Gross Value Added of Domestic Corporate Business in Current Dollars and Gross Value Added of Nonfinancial Domestic Corporate Business in Current and Chained Dollars, US Bureau of Economic Analysis (Accessed October 20, 2022), https://bit.ly/3DHVdNT.

[12] Id.

[13] Top Corporations in Major CPI Categories Rewarded Shareholders With Over $140 Billion After Raising Prices on Consumers, Accountable US (March 10, 2022), https://bit.ly/3zpYpv5.

[14] Id.

[15] Membership, Pharmaceutical Research and Manufacturers of America (Viewed on Oct. 28,2022), https://phrma.org/About.

[16] Form 990, Schedule I, Grants and Other Assistance to Organizations, Governments and Individuals in the United States, Internal Revenue Service (2019), https://bit.ly/3sDlcQ8.

[17] Michael Beckel, Dark Money Illuminated, Database of Dark Money Donors, Issue One (Sept. 11, 2018), https://bit.ly/3zpvEhU and https://bit.ly/3WottFo.

[18] Michael Beckel, Dark Money Illuminated, Database of Dark Money Donors, Issue One (Sept. 11, 2018), https://bit.ly/3zpvEhU and https://bit.ly/3WottFo.

[19] Krystal Hur, Pharma-Backed ‘Dark Money’ Group Hits House Dems on Drug Pricing Plan, OpenSecrets (May 13, 2021), https://bit.ly/3NfaGIl.

[20] AAN Launches $4 Million+ Campaign in Over 40 Districts To Stop Pelosi’s Socialist Drug Takeover Plan, American Action Network (May 6, 2021), https://bit.ly/3U2vxkV.

[21] Form 990, Schedule I, Grants and Other Assistance to Organizations, Governments and Individuals in the United States, Internal Revenue Service (2019), https://bit.ly/3sDlcQ8.

[22] Form 990, Schedule I, Grants and Other Assistance to Organizations, Governments and Individuals in the United States, Internal Revenue Service (2018), https://bit.ly/3Dmc870.

[23] Form 990, Schedule I, Grants and Other Assistance to Organizations, Governments and Individuals in the United States, Internal Revenue Service (2017), https://bit.ly/3NinSfA.

[24] Actions, H.R.5376 – Inflation Reduction Act of 2022, Congress.gov, https://bit.ly/3gUZrbN.

[25] Jane G. Gravelle and Molly F. Sherlock, Crude Oil Windfall Profits Taxes: Background and Policy Considerations, Congressional Research Service (March 23, 2022), https://bit.ly/3Wa546e.

Follow-up Comments to the FDA Regarding CDER’s Proposal to Withdraw Approval of Makena (Hydroxyprogesterone Caproate)

Testimony on Cryptocurrency Mining in Texas

View as PDF

In follow-up comments to the Food and Drug Administration regarding the Center for Drug Evaluation and Research’s (CDER’s) proposal to withdraw approval of Makena (hydroxyprogesterone caproate) for prevention of preterm labor, Public Citizen urged the agency to take prompt regulatory action as soon as the approval of Makena is withdrawn to prevent the predictable pharmacy compounding of hydroxyprogesterone caproate for prevention of preterm birth.

See Public Citizen’s other work on hydroxyprogesterone caproate (Makena).